APC501

APC501 is a preclinical-stage small molecule drug candidate developed by Andros Pharmaceuticals for the management of acute pain. It functions as a sodium channel blocker or modulator, targeting voltage-gated sodium channels in peripheral nerves to inhibit the conduction of pain impulses. The drug is formulated for topical administration using Andros's proprietary lipid-based drug delivery platform, which employs microencapsulation technology to optimize the delivery of the active agent through the skin. APC501 is specifically being developed as a topical anesthetic to mitigate pain associated with minor medical procedures, such as intravenous catheter placement and venipuncture.